Asian Spectator

.
Business Advice

.

ECOVACS Reimagines the Future of Home Cleaning with the launch of an Extensive Range of Innovative Products Designed for City Dwellers

ECOVACS unveils two new robotic vacuums - the DEEBOT T30 PRO OMNIand DEEBOT X2 COMBO - specially designed to tackle cleaning challenges faced by city dwellers First 100 customers to purcha...

Copan, putting Covid-19 challenges behind and setting up for t...

BRESCIA, Italy, April 10, 2021 /PRNewswire-AsiaNet/ -- With an email to the main distributors, Copan group's CEO describes how the ramp-up of Covid-19-related products has been concluded, an...

DHL Delivers First Batch of COVID-19 Vaccines to Singapore

Rigorous planning and testing to ensure supply chain supports vaccine's stringent temperature requirements SINGAPORE - Media OutReach - 21 December 2020 - DHL, the leading global bra...

China's retail giant Suning signs deals with overseas brands a...

SHANGHAI, Nov. 7, 2019 /PRNewswire-AsiaNet/ -- - Will open experiential stores focusing on overseas emerging brands in China in next 3 years to promote overseas brands - Chinese giant deepen...

Hong Kong Trade Development Council Chairman Dr Peter KN Lam confident in Hong Kong's business environment

HONG KONG, Jul 20, 2021 - (ACN Newswire) - The Hong Kong Trade Development Council (HKTDC) noticed recent discussions on Hong Kong's business environment. Dr Peter KN Lam, Chairman of the H...

Floating Solar: Philippines Switches On It's First Hybrid Floa...

SUZHOU, China, July 16, 2019 /PRNewswire-AsiaNet/ -- The Philippines first 200kw floating solar power project by Ocean Sun, a leading solar energy company based in Norway, was recently switc...

Jiangsu Traditional Chinese Medicine International Exchange Co...

NANJING, China, Nov. 23, 2022 /Xinhua-AsiaNet/-- On November 21st, the "Jiangsu Traditional Chinese Medicine International Exchange Conference" jointly sponsored by the Foreign Affairs Offic...

Dreame Technology to Launch the Wet and Dry Vacuum that Simpli...

BEIJING, Sept. 30, 2021 /PRNewswire-AsiaNet/ -- Dreame Technology, a global leading brand in smart home cleaning appliances, is launching its groundbreaking H11 product series with the Dream...

Ministry of Tourism and Creative Economy Will Implement CHS Pr...

BALI,Indonesia,May 25,2020/PRNewswire-AsiaNet/-- Ministry of Tourism and Creative Economy(http://www.kemenparekraf.go.id/) is going to implement CHS (Cleanliness, Health, and Safety) program...

Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China

Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China

TOKYO, Apr 1, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku.

On the basis of this agreement, the companies will jointly develop SI-613 in China for a treatment of knee osteoarthritis. After obtaining approval, Seikagaku will supply products to Eisai, and Eisai will be responsible for distribution. The companies will cover an equal share of the development cost, and Eisai will pay Seikagaku the upfront payment, and development as well as sales milestones.

Osteoarthritis is a disease caused by the articular cartilage damage due to aging and other factors, leading to inflammation and pain, which result in impaired quality of life (QOL). Knee osteoarthritis is one of the most frequent cases among thereof, and the number of symptomatic patients with knee osteoarthritis in China is estimated to be approximately 47 million(1), and it is anticipated that the number will continue to increase as the population ages.

SI-613 is diclofenac conjugated sodium hyaluronate created by Seikagaku using their proprietary drug-binding technology to chemically bond hyaluronic acid and diclofenac (an anti-inflammatory drug).

This material has the analgesic and anti-inflammatory effects of diclofenac, which is designed to be 23 sustained-released(2) by a drug delivery system(3), in addition to the joint function improving effect of sodium hyaluronate. Hence, it is expected that SI-613 rapidly and continuously reduces the pain and inflammation associated with osteoarthritis.

Under this agreement, Eisai aims to contribute to patients with knee osteoarthritis that is unmet medical needs by utilizing the knowledge and networks that Eisai has cultivated through its China business. Seikagaku will seek to maximize the value of SI-613 in China by leveraging Eisai's business base in China.

Through the development and commercialization of SI-613, the companies will provide new treatment options in China for knee osteoarthritis and contribute to improving the QOL of patients.

(1) For the estimated data regarding the number of patients with knee osteoarthritis Data of morbidity prevalence rate - The Prevalence of Symptomatic Knee Osteoarthritis in China, ARTHRITIS & RHEUMATOLOGY(2016) Estimated data calculated from United Nations World Population Estimates - World Population Prospects, URL:http://www.un.org/en/development/desa/population/ (2) Sustained release is a gradual release of the active pharmaceutical ingredients of a drug to achieve a sustained therapeutic effect. (3) Drug delivery system (DDS) is a technology for the controlled release, targeting, and absorption improvement of drugs.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Dampak penyebaran teror: bagaimana ketakutan mengubah pikiran kita

Anas-Mohammed/ShutterstockPada Mei 1097, tentara salib melemparkan kepala-kepala tahanan yang dipenggal ke atas tembok Nicaea, Turki. Tujuan dari aksi ini adalah untuk meneror para pembela dan menaklu...

Apakah memiliki anak membuatmu lebih bahagia? Ini kata penelitian

The happiness and fulfilment you feel with the decision will depend on many different factors.CeltStudio/ ShutterstockKepercayaan yang berkembang di berbagai belahan dunia adalah bahwa memiliki anak a...

Cek Fakta: Prabowo mengklaim rasio pajak Indonesia di bawah negara tetangga. Benarkah?

Ekie E Sularso/Shutterstock‘Tax ratio’ kita banyak bisa di-‘improve’ sekarang 10% dan tetangga kita di 16%, Thailand Malaysia 16%, Vietnam-Kamboja sekitar 16%, 17%, 18%.–...



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion